JPH07309765A - Body fat accumulation inhibitor - Google Patents
Body fat accumulation inhibitorInfo
- Publication number
- JPH07309765A JPH07309765A JP10275994A JP10275994A JPH07309765A JP H07309765 A JPH07309765 A JP H07309765A JP 10275994 A JP10275994 A JP 10275994A JP 10275994 A JP10275994 A JP 10275994A JP H07309765 A JPH07309765 A JP H07309765A
- Authority
- JP
- Japan
- Prior art keywords
- fat
- xylose
- body fat
- arabinose
- accumulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 25
- 238000009825 accumulation Methods 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title claims abstract description 9
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 43
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 24
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 19
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 210000004003 subcutaneous fat Anatomy 0.000 abstract description 8
- 208000008589 Obesity Diseases 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 235000020824 obesity Nutrition 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000013078 crystal Substances 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 229920002472 Starch Polymers 0.000 abstract description 2
- 238000007865 diluting Methods 0.000 abstract description 2
- 230000001603 reducing effect Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000008107 starch Substances 0.000 abstract description 2
- 235000019698 starch Nutrition 0.000 abstract description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000015094 jam Nutrition 0.000 description 2
- 210000000574 retroperitoneal space Anatomy 0.000 description 2
- 241000609240 Ambelania acida Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】この発明は体脂肪蓄積抑制剤に関
するものであり、詳細にはＤ−キシロースおよび／また
はＬ−アラビノースを有効成分とする体脂肪蓄積抑制
剤、体脂肪減少剤に関するものである。FIELD OF THE INVENTION The present invention relates to a body fat accumulation inhibitor, and more particularly to a body fat accumulation inhibitor and a body fat reducing agent containing D-xylose and / or L-arabinose as an active ingredient. is there.
【０００２】[0002]
【従来の技術】肥満は、高血圧、耐糖能異常、高脂血症
などを合併しやすく、虚血性心疾患、脳卒中、糖尿病な
どの危険因子と考えられており、成人病予防の観点か
ら、肥満対策はきわめて重要である。肥満とは、単に体
重が多いことではなく、体構成成分の内、脂肪組織の占
める割合（体脂肪率）が正常以上に増加した状態として
定義されている。そして近年、皮下脂肪、内臓脂肪等の
体脂肪の蓄積について、皮下組織にたまる皮下脂肪型肥
満よりも、臓器の間にたまる内臓脂肪型肥満の方が高血
圧、高脂血症、糖尿病などの成人病を合併しやすいこと
も報告されている。［徳永勝人・他：日本内科学会誌８
１巻 ９５−９９頁（１９９２年）。］この発明者等は
皮下脂肪、内臓脂肪等の体脂肪に対する各種薬剤の効果
を検討した所、Ｄ−キシロースおよび／またはＬ−アラ
ビノースに、体脂肪の蓄積を抑制する作用があるという
新知見を得、さらに鋭意研究を進めた結果、この発明を
完成した。BACKGROUND ART Obesity is easily associated with hypertension, impaired glucose tolerance, hyperlipidemia, etc., and is considered to be a risk factor for ischemic heart disease, stroke, diabetes, etc. Countermeasures are extremely important. Obesity is defined as a state in which the proportion of adipose tissue (body fat percentage) in body components is increased more than normal, rather than simply being heavy. In recent years, with regard to the accumulation of body fat such as subcutaneous fat and visceral fat, visceral fat obesity that accumulates between organs is more common in adults with hypertension, hyperlipidemia, diabetes, etc. than subcutaneous fat obesity that accumulates in subcutaneous tissues. It is also reported that the disease is likely to be complicated. [Katsuhito Tokunaga et al .: Journal of the Japanese Society of Internal Medicine 8
Volume 1, pages 95-99 (1992). The present inventors examined the effect of various drugs on body fat such as subcutaneous fat and visceral fat, and found that D-xylose and / or L-arabinose has a new effect of suppressing body fat accumulation. As a result of further earnest research, the present invention was completed.
【０００３】[0003]
【発明の構成】この発明は、Ｄ−キシロースおよび／ま
たはＬ−アラビノースを有効成分とする体脂肪蓄積抑制
剤、体脂肪減少剤を提供する。The present invention provides a body fat accumulation inhibitor and a body fat reducing agent containing D-xylose and / or L-arabinose as an active ingredient.
【０００４】この発明で使用するＤ−キシロースおよび
Ｌ−アラビノースは粉末、液状、結晶あるいは顆粒のい
ずれであってもよいし、米ヌカ、小麦フスマ、バガス
（さとうきびのしぼりかす）、とうもろこし外皮、綿実
殻等の加水分解物のＤ−キシロースおよびＬ−アラビノ
ース粗抽出物であってもよい。Ｄ−キシロースとＬ−ア
ラビノースを混合して使用する場合、両者の混合割合は
一般的には限定はないが、工業的には、例えば上記粗抽
出物を使用する場合、Ｄ−キシロースとＬ−アラビノー
スの割合は５０：５０ないし９９：１、好ましくは８
０：２０ないし９９：１の範囲が考えられる。The D-xylose and L-arabinose used in the present invention may be in the form of powder, liquid, crystals or granules, rice bran, wheat bran, bagasse (squeeze of sugar cane), corn rind and cotton. It may be a D-xylose and L-arabinose crude extract of a hydrolyzate such as a nut shell. When D-xylose and L-arabinose are used as a mixture, the mixing ratio of both is generally not limited, but industrially, for example, when the above crude extract is used, D-xylose and L-arabinose are mixed. The ratio of arabinose is 50:50 to 99: 1, preferably 8
A range of 0:20 to 99: 1 is possible.
【０００５】Ｄ−キシロースおよびＬ−アラビノースは
それぞれ単独あるいは両者を併用して体脂肪（皮下脂
肪、内臓脂肪）蓄積抑制剤として、体脂肪（皮下脂肪、
内臓脂肪）減少剤として使用することができる。これら
の用途で用いる場合には、例えばＤ−キシロース及び／
またはＬ−アラビノースの粉末、液状、結晶あるいは顆
粒をそのまま、あるいは水、エタノール、エチレングリ
コール、ポリエチレングリコール等の液状担体、澱粉、
セルロース、ポリアミド粉末等の固型担体等の無毒性担
体で希釈して、アンプル剤、顆粒剤、錠剤、丸剤、カプ
セル剤、シロップ剤等に常法にしたがって調製したもの
をＤ−キシロースおよび／またはＬ−アラビノースとし
て０．０１ｇ／ｋｇ以上投与するようにすればよい。D-xylose and L-arabinose may be used alone or in combination of both as body fat (subcutaneous fat, visceral fat) accumulation suppressors.
It can be used as a visceral fat) reducing agent. When used for these purposes, for example, D-xylose and / or
Alternatively, L-arabinose powder, liquid, crystals or granules as they are, or liquid carrier such as water, ethanol, ethylene glycol, polyethylene glycol, starch,
D-xylose and / or an ampoule, a granule, a tablet, a pill, a capsule, a syrup and the like prepared by diluting with a non-toxic carrier such as a solid carrier such as cellulose and polyamide powder Alternatively, 0.01 g / kg or more of L-arabinose may be administered.
【０００６】この発明の体脂肪蓄積抑制剤、体脂肪減少
剤は、上記のようにそれらを単独で人または動物に投与
することもできるが、一般の食品に添加して使用するこ
ともできる。例えば、Ｄ−キシロースおよび／またはＬ
−アラビノースを直接もしくは上記のような担体とを常
法に従って調製したものを各種食品、例えば清涼飲料
水、コーヒー、紅茶、果汁、牛乳、ジャム、あん、ゼリ
ー、菓子、コーンフレークなどの液状或いは固状の食
品、調味料、副食品等に添加して使用することもでき
る。The body fat accumulation suppressor and body fat reducer of the present invention can be administered alone to humans or animals as described above, or can be used by adding them to general foods. For example, D-xylose and / or L
-Arabinose prepared directly or with a carrier as described above according to a conventional method for various foods, such as soft drinks, coffee, tea, fruit juice, milk, jam, bean jam, jelly, confectionery, corn flakes, etc. It can also be used by adding it to foods, seasonings, side foods, etc.
【０００７】[0007]
【発明の効果】この発明の体脂肪（皮下脂肪、内臓脂
肪）蓄積抑制剤、体脂肪（皮下脂肪、内臓脂肪）減少剤
を使用することにより、体脂肪とくに内臓脂肪の蓄積が
抑制され、また内臓脂肪の減少効果が顕著になり、肥
満、高血圧、高脂血症等の健康障害を予防することがで
きる。The use of the body fat (subcutaneous fat, visceral fat) accumulation suppressor and body fat (subcutaneous fat, visceral fat) reducer of the present invention suppresses the accumulation of body fat, particularly visceral fat, and The visceral fat reducing effect becomes remarkable, and health disorders such as obesity, hypertension, and hyperlipidemia can be prevented.
【０００８】次にこの発明の効果を試験例により説明す
る。 試験例１ 内臓脂肪蓄積に対するキシロースの効果（ラット）：ラ
ット（ウイスター雄、６週令、体重約２１０ｇ）を１群
４匹とし、計１２匹使用した。飼料はＣＥ−２（日本ク
レア（株））（組成は下に示す通り）を使用し、１群
（対照）には、ＣＥ−２に砂糖２０％及びセルロース２
０％添加したものを与え、２群にはＣＥ−２に砂糖２０
％、セルロース１０％、Ｄ−キシロース１０％を添加し
たものを、３群にはＣＥ−２に砂糖２０％及びＤ−キシ
ロース２０％を添加したものを与えて、１０週間飼育し
た。飼育後屠殺・解剖し、副睾丸の周囲及び後腹膜の脂
肪をとりだし、重量を測定し、体重１００ｇ当りに補正
したものを脂肪率とした。結果は以下の通りである。Next, the effects of the present invention will be described with reference to test examples. Test Example 1 Effect of xylose on visceral fat accumulation (rat): Rats (male Wistar, 6-week-old, body weight: about 210 g) were made up of 4 rats per group, and 12 rats in total were used. CE-2 (CLEA Japan, Inc.) (composition as shown below) was used as the feed, and CE-2 had 20% sugar and 2 cellulose as a group (control).
0% added to the 2 groups CE-2 and sugar 20
%, Cellulose 10% and D-xylose 10% were added, and to group 3 were given CE-2 with 20% sugar and 20% D-xylose added, and were bred for 10 weeks. After rearing, the animals were slaughtered and dissected, and the fat around the epididymis and the retroperitoneum were taken out, weighed, and corrected for 100 g of body weight to obtain the fat percentage. The results are as follows.
【０００９】[0009]
【表１】 [Table 1]
【００１０】飼料組成： 水 分（％） ８．７ 粗 蛋 白 質（％） ２４．８ 粗 脂 肪（％） ４．４ 粗 繊 維（％） ３．５ 粗 灰 分（％） ７．０ 可溶性無窒素物（％） ５１．６Feed composition: Water (%) 8.7 Crude protein (%) 24.8 Crude fat (%) 4.4 Crude fiber (%) 3.5 Crude ash (%) 7. 0 Soluble nitrogen-free (%) 51.6
【００１１】試験例２ ラット（ウィスター、雄、８週令、体重約２９０ｇ）を
１群４匹とし、計１６匹使用した。飼料はＣＥ−２（日
本クレア（株））（組成は下に示す通り）を使用し、１
群（対照）には、ＣＥ−２に砂糖２０％及びセルロース
１０％添加したものを与え、２群にはＣＥ−２に砂糖２
０％及びＬ−アラビノース１０％を添加したものを、３
群にはＣＥ−２に砂糖２０％及びＤ−キシロース９％、
Ｌ−アラビノース１％を添加したものを、４群にはＣＥ
−２に砂糖２０％及びＤ−キシロース１０％添加したも
のを与え、４週間飼育した。飼育後屠殺、解剖し、内蔵
脂肪（副睾丸の周囲及び後腹膜、腸管膜の脂肪）と皮下
脂肪（腹部）を取り出し、重量を測定し、体重１００ｇ
当りに補正したものを、脂肪率とした。結果は以下の通
りである。 飼料組成： 水 分（％） ８．７ 粗 蛋 白 質（％） ２４．８ 粗 脂 肪（％） ４．４ 粗 繊 維（％） ３．５ 粗 灰 分（％） ７．０ 可溶性無窒素物（％） ５１．６Test Example 2 Rats (Wistar, male, 8 weeks old, weight: about 290 g) were made up of 4 rats per group, and 16 rats were used in total. The feed used was CE-2 (CLEA Japan, Inc.) (composition as shown below).
The group (control) was given CE-2 with 20% sugar and 10% cellulose added, and 2 groups were given CE-2 and sugar 2
Add 0% and L-arabinose 10% to 3
The group had CE-2 with 20% sugar and 9% D-xylose,
L-arabinose 1% was added to the 4 groups CE
-2 was added with 20% sugar and 10% D-xylose and fed for 4 weeks. After breeding, the animals are slaughtered and dissected, visceral fat (adipose around epididymis, retroperitoneum, and mesentery) and subcutaneous fat (abdomen) are taken out, weighed, and weighed 100 g.
The value corrected for the hit was defined as the fat percentage. The results are as follows. Feed composition: Water (%) 8.7 Crude protein (%) 24.8 Crude fat (%) 4.4 Crude fiber (%) 3.5 Crude ash (%) 7.0 Soluble Nitrogen (%) 51.6
【００１２】[0012]
【表２】 [Table 2]
Claims (2)
ビノースを有効成分として含有する体脂肪蓄積抑制剤。1. A body fat accumulation inhibitor containing D-xylose and / or L-arabinose as an active ingredient.
ビノースを有効成分として含有する体脂肪減少剤。2. A body fat reducing agent containing D-xylose and / or L-arabinose as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10275994A JPH07309765A (en) | 1994-05-17 | 1994-05-17 | Body fat accumulation inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10275994A JPH07309765A (en) | 1994-05-17 | 1994-05-17 | Body fat accumulation inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07309765A true JPH07309765A (en) | 1995-11-28 |
Family
ID=14336132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10275994A Pending JPH07309765A (en) | 1994-05-17 | 1994-05-17 | Body fat accumulation inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07309765A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724842A3 (en) * | 1994-12-15 | 1997-02-12 | Antonio Picarelli | Preparation for the treatment of obesity |
| WO2000044754A1 (en) * | 1999-01-29 | 2000-08-03 | Sumitomo Chemical Company, Limited | Fat accumulation inhibitory agents |
| JP2002154967A (en) * | 2000-11-15 | 2002-05-28 | Makoto Fujii | Therapeutic agent for diabetes mellitus |
| EP1167536A4 (en) * | 2000-02-01 | 2005-08-03 | Unitika Ltd | Process for producing l-arabinose, l-arabinose-containing enzymatically processed products, diet foods, diabetic diet foods and fruit or vegetable juices and process for producing the same |
| US8071141B2 (en) | 2000-12-12 | 2011-12-06 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2013172711A (en) * | 2012-01-26 | 2013-09-05 | Kanazawa Inst Of Technology | Antioxidant composition, composition inhibiting activity of disaccharide hydrolase, composition for intestinal regulation, diet composition, food and drink, and method of selectively producing arabinose |
-
1994
- 1994-05-17 JP JP10275994A patent/JPH07309765A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724842A3 (en) * | 1994-12-15 | 1997-02-12 | Antonio Picarelli | Preparation for the treatment of obesity |
| WO2000044754A1 (en) * | 1999-01-29 | 2000-08-03 | Sumitomo Chemical Company, Limited | Fat accumulation inhibitory agents |
| EP1167536A4 (en) * | 2000-02-01 | 2005-08-03 | Unitika Ltd | Process for producing l-arabinose, l-arabinose-containing enzymatically processed products, diet foods, diabetic diet foods and fruit or vegetable juices and process for producing the same |
| JP2002154967A (en) * | 2000-11-15 | 2002-05-28 | Makoto Fujii | Therapeutic agent for diabetes mellitus |
| US8071141B2 (en) | 2000-12-12 | 2011-12-06 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2013172711A (en) * | 2012-01-26 | 2013-09-05 | Kanazawa Inst Of Technology | Antioxidant composition, composition inhibiting activity of disaccharide hydrolase, composition for intestinal regulation, diet composition, food and drink, and method of selectively producing arabinose |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5607397B2 (en) | Composition for preventing or ameliorating multiple risk factor syndrome | |
| EP2625968A1 (en) | Composition and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety | |
| US20180264020A1 (en) | Composition for prevention, amelioration or treatment of metabolic syndrome | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| JPH07242551A (en) | Agent for inhibiting accumulation of body fat | |
| JPH07309765A (en) | Body fat accumulation inhibitor | |
| WO2007142230A1 (en) | Lipid-metabolism-improving agent | |
| JP2012001516A (en) | Composition containing coix seed protein having lipid/carbohydrate metabolism improving action | |
| JPH11180869A (en) | Blood lipid improving agent, cyclic amp phosphodiesterase inhibitor, drink and food, and skin preparation for external use | |
| TWI465245B (en) | Peptides with antidiabetic effect and their use | |
| US20060034781A1 (en) | Peroral preparation for prevention or treatment of atopic dermatatis | |
| US20080058264A1 (en) | Amino-acid containing composition for inhibiting accumulation of fat | |
| JPH05186356A (en) | Diet lipid digestive absorption inhibitor and food/ beverage containing the same | |
| JP5158779B2 (en) | Antihypertensive agent comprising D-allose as an active ingredient | |
| JPH11147828A (en) | Cholesterol and lipid absorption inhibitors | |
| JP3234113B2 (en) | Blood glucose elevation inhibitors and uses | |
| JPS60186261A (en) | Solid food composition | |
| JP2012162472A (en) | Lipid eliminant | |
| JP3345650B2 (en) | Hypertension inhibitor | |
| JP2008231080A (en) | Leptin secretion promoter from adipocytes | |
| WO2008029869A1 (en) | Agent for prevention or treatment of blood glucose level elevation | |
| JP2003261445A (en) | Blood neutral fat reducing agent | |
| McCARTY | Dietary glycemic index may influence cancer risk by modulating IGF-I activity: a hypothesis | |
| KR20250162070A (en) | Compositions for improving or treating dyslipidemia and dyslipidemia-related diseases comprising phloretic acid | |
| JP2010105948A (en) | Fatty liver inhibitor |